2024 Here we go again., page-524

Thanks for your comments @Phaedrus and @dachopper.

Since the ARDS trial, I have been curious as to whether Remestemcel-L combined with corticosteroids may exhibit the same synergistic effects that were observed in the ARDS trial in other indications such as AGvHD.

Steroids will be cheaper as a first-line therapy. However, as we gain more insight regarding mechanism of action and the characteristics that identify patients who are likely to benefit from Rem-L (e.g. high MAP scores, inflammatory biomarkers), it seems quite plausible that doctors could prescribe it as a first-line therapy for those target population - particularly in severe cases. This paper provides a nice summary of recent progress that has been made to identify metrics for stratification of patients for MSC therapies: https://www.sciencedirect.com/science/article/pii/S1465324923010496